MS
SAGE

Maven Securities’s Sage Therapeutics SAGE Stock Holding History

Maven Securities’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-7,572
Closed -$577K – 1297
2021
Q1 		$577K Buy
+7,572
New +$621K 0.03% 588
2020
Q1 		– Sell
-62,700
Closed -$4.55M – 422
2019
Q4 		$4.55M Buy
+62,700
New +$7.71M 0.41% 43
2018
Q4 		– Sell
-1,531
Closed -$213K – 159
2018
Q3 		$213K Buy
+1,531
New +$236K 0.08% 140

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Maven Securities's SAGE Position: Q2 2021 in Review

Maven Securities sold out of Sage Therapeutics (SAGE) in Q2 2021, closing a stake of 7,572 shares — an estimated $577K sold.

Maven Securities first reported a position in SAGE in Q3 2018 and held it in 3 quarters. The position peaked at $4.55M in Q4 2019. 256 funds tracked by Wall St. Rank hold SAGE as of Q2 2021.

  • Maven Securities reported no remaining Sage Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Maven Securities sold 7,572 Sage Therapeutics shares in Q2 2021, an estimated $577K.
  • Maven Securities first reported a position in Sage Therapeutics in Q3 2018 and held it in 3 quarters.
  • Maven Securities's Sage Therapeutics position peaked at $4.55M in Q4 2019.
  • 256 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2021.

Based on Maven Securities's 13F filing for Q2 2021, filed 16 Aug 2021.